Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

23andMe Recruiting for Depression, Bipolar Study

By Ryan Bushey | August 4, 2017

A well-known consumer genetic testing firm has initiated enrollment for a novel study aimed at exploring the biological underpinnings of major depressive and bipolar disorders.

23andMe is working with the Milken Institute and Lundbeck Pharmaceuticals on a trial that seeks to recruit 25,000 people diagnosed with these conditions, which will be split between 15,000 participants with major depressive disorder and 10,000 people with bipolar disorder.

Here’s how this experiment will work.

Participants will provide a saliva sample for DNA genotyping, and then complete nine monthly cognitive assessment sessions varying between 10 to 30 minutes in length. In return, they’ll receive complimentary access to 23andMe’s Personal Genome Service that includes over 75 personalized genetic reports about their health, traits, and ancestry.

The de-identified data that emerges from these tests will be analyzed for clues pertaining to how genetics and environmental factors combine to impact brain function and behavior.

“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said 23andMe’s Emily Drabant Conley, PhD., the Vice President of Business Development, in a statement. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”

More than 16 million people are living with major depressive disorder in the U.S. while nearly 6 million Americans suffer from bipolar disorder. There are clues to what may cause these disorders but nothing concrete has been determined so the outcome of this study could identify specific factors that induce these disorders.

“We look forward to leveraging our patient advocacy network and social following to help drive awareness and recruitment efforts for the 23andMe study,” said Melissa Stevens, the executive director of the Milken Institute’s Center for Strategic Philanthropy. “Moreover, we are excited to better understand the disease biology of bipolar and major depressive disorders as doing so will help us guide philanthropists to maximize the return on their mental health giving programs.”

23andMe has made progress in identifying genetic links to depression in the past. Last year, it co-authored a study with researchers at the Massachusetts General Hospital that revealed 15 locations in the human genome associated with the development of major depressive disorder.

No deadline has been set for when this study could conclude, but it’s open to anyone between the ages of 18 to 50 who has been diagnosed by a physician with one of these conditions, has been prescribed medication for it, lives in the U.S., and has easy access to the internet.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE